WCLC 2025 - Posters & ePosters-P3.03.34 Assessment of Minimal Residual Disease Using Liquid Biopsy in Patients With EGFR-Mutated Lung Cancer Treated With Osimertinib

P3.03.34 Assessment of Minimal Residual Disease Using Liquid Biopsy in Patients With EGFR-Mutated Lung Cancer Treated With Osimertinib

Asset Subtitle

Celia Delahaye

Meta Tag

Speaker Celia Delahaye

Topic Tumor Biology – Translational Biology